Today, Leerink Swann Reiterates Outperform Rating for Eli Lilly and Co. (LLY)

Today, Leerink Swann Reiterates Outperform Rating for Eli Lilly and Co. (LLY)

Eli Lilly and Co. (NYSE:LLY)‘s stock had its “outperform” rating restated by analysts at Leerink Swann in a note issued to investors on Saturday. They currently have a $92.00 price target on the stock, down from their prior price target of $102.00. Leerink Swann’s price target points to a potential upside of 33.10% from the company’s previous close.

LLY has been the topic of several other research reports. BMO Capital Markets reaffirmed a “buy” rating and set a $94.00 target price on shares of Eli Lilly and in a research report on Monday, October 3rd. Jefferies Group reissued a “buy” rating and issued a $100.00 price objective (down previously from $105.00) on shares of Eli Lilly and in a research report on Friday, October 28th. Citigroup Inc. reissued a “buy” rating on shares of Eli Lilly and in a research report on Tuesday, November 8th. JPMorgan Chase & Co. raised Eli Lilly and from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $92.00 to $95.00 in a research report on Thursday, September 8th. Finally, Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Wednesday, October 5th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Eli Lilly and currently has a consensus rating of “Buy” and an average price target of $108.34.

Eli Lilly and (NYSE:LLY) traded up 1.65% during mid-day trading on Friday, hitting $69.12. The stock had a trading volume of 8,620,682 shares. The stock has a market capitalization of $73.11 billion, a P/E ratio of 30.07 and a beta of 0.28. The company’s 50 day moving average is $76.69 and its 200-day moving average is $77.92. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $88.16.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.96 by $0.08. The company had revenue of $5.19 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.89 EPS. On average, analysts expect that Eli Lilly and will post $3.55 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be given a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 2.95%. The ex-dividend date is Thursday, November 10th. Eli Lilly and’s payout ratio is 88.70%.

In related news, insider Maria A. Crowe sold 2,248 shares of the business’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now directly owns 94,319 shares in the company, valued at $7,674,737.03. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. BlueMountain Capital Management LLC acquired a new position in Eli Lilly and during the first quarter valued at approximately $482,000. Iowa State Bank purchased a new position in Eli Lilly and during the second quarter worth about $104,000. Stock Yards Bank & Trust Co. boosted its position in Eli Lilly and by 11.0% in the second quarter. Stock Yards Bank & Trust Co. now owns 22,976 shares of the company’s stock worth $1,810,000 after buying an additional 2,283 shares during the last quarter. New England Research & Management Inc. purchased a new position in Eli Lilly and during the second quarter worth about $583,000. Finally, Park National Corp OH boosted its position in Eli Lilly and by 12.7% in the second quarter. Park National Corp OH now owns 100,178 shares of the company’s stock worth $7,889,000 after buying an additional 11,283 shares during the last quarter. Institutional investors and hedge funds own 75.11% of the company’s stock.

About Eli Lilly and

Related posts

Leave a Comment